CooperCompanies announces a $1 billion increase in its share repurchase program, now totaling $2 billion.
Quiver AI Summary
CooperCompanies announced an increase of $1 billion to its share repurchase program, bringing the total to $2 billion. This decision, made by the Board of Directors, highlights the company's strong financial position and commitment to enhancing shareholder value while maintaining investments and reducing debt. CEO Al White emphasized the company's confidence in its long-term growth trajectory. The repurchases will depend on market conditions and can take place through open market transactions or privately negotiated deals. The program has no termination date and can be suspended or adjusted at any time. CooperCompanies operates globally with two main segments, CooperVision and CooperSurgical, aiming to positively impact over fifty million lives annually.
Potential Positives
- CooperCompanies announced a $1 billion increase in its share repurchase program, signaling strong confidence in its financial health.
- The total share repurchase program now amounts to $2 billion, enhancing the company's commitment to returning capital to shareholders.
- This move reflects the Board's confidence in Cooper's long-term growth trajectory and disciplined capital allocation strategy.
- The company maintains a robust balance sheet and cash flow generation, which supports continued investments and debt reduction alongside share repurchases.
Potential Negatives
- The share repurchase program may indicate the company is prioritizing returning capital to shareholders over investing in growth opportunities.
- The absence of a termination date for the repurchase program may raise concerns about the company's commitment to maintaining its balance sheet and managing debt effectively.
- Forward-looking statements highlight inherent risks and uncertainties, suggesting that future plans could significantly deviate from current expectations.
FAQ
What is the new total amount of CooperCompanies' share repurchase program?
The share repurchase program now totals $2 billion following the $1 billion increase approved by the Board of Directors.
Who announced the share repurchase program increase?
The increase was announced by Al White, President and Chief Executive Officer of CooperCompanies.
How does the share repurchase align with CooperCompanies' strategy?
The share repurchase reflects CooperCompanies' commitment to enhancing shareholder value while continuing to invest and reduce debt.
Are there any obligations for CooperCompanies to repurchase shares?
No, the program does not obligate CooperCompanies to acquire any amount of common stock and may be suspended at any time.
What factors might affect the timing of share repurchases?
The timing and total amount of share repurchases will depend on market conditions and may involve open market or private purchases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$COO Congressional Stock Trading
Members of Congress have traded $COO stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $COO stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 05/15.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$COO Insider Trading Activity
$COO insiders have traded $COO stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $COO stock by insiders over the last 6 months:
- ALBERT G III WHITE (President & CEO) purchased 10,000 shares for an estimated $683,900
- DANIEL G MCBRIDE (EVP & Chief Operating Officer) purchased 3,000 shares for an estimated $195,120
- GERARD H III WARNER (President, CooperVision, Inc.) purchased 1,450 shares for an estimated $100,383
- BRIAN G ANDREWS (EVP, CFO & Treasurer) purchased 1,525 shares for an estimated $100,162
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$COO Hedge Fund Activity
We have seen 318 institutional investors add shares of $COO stock to their portfolio, and 415 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VERITAS ASSET MANAGEMENT LLP removed 3,847,698 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $273,802,189
- SUSTAINABLE GROWTH ADVISERS, LP added 3,385,059 shares (+inf%) to their portfolio in Q2 2025, for an estimated $240,880,798
- GENERATION INVESTMENT MANAGEMENT LLP removed 2,873,376 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $204,469,436
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,592,441 shares (+65.6%) to their portfolio in Q2 2025, for an estimated $184,478,101
- JPMORGAN CHASE & CO removed 2,481,717 shares (-47.9%) from their portfolio in Q2 2025, for an estimated $176,598,981
- VIKING GLOBAL INVESTORS LP removed 2,025,310 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $170,834,898
- NORGES BANK removed 1,877,646 shares (-79.2%) from their portfolio in Q2 2025, for an estimated $133,613,289
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$COO Analyst Ratings
Wall Street analysts have issued reports on $COO in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 08/28/2025
- Baird issued a "Outperform" rating on 08/28/2025
- Wells Fargo issued a "Overweight" rating on 08/28/2025
- Piper Sandler issued a "Overweight" rating on 08/28/2025
- Needham issued a "Buy" rating on 08/28/2025
- Mizuho issued a "Outperform" rating on 07/16/2025
To track analyst ratings and price targets for $COO, check out Quiver Quantitative's $COO forecast page.
$COO Price Targets
Multiple analysts have issued price targets for $COO recently. We have seen 9 analysts offer price targets for $COO in the last 6 months, with a median target of $83.0.
Here are some recent targets:
- Joanne Wuensch from Citigroup set a target price of $72.0 on 08/28/2025
- Patrick Wood from Morgan Stanley set a target price of $76.0 on 08/28/2025
- David Saxon from Needham set a target price of $94.0 on 08/28/2025
- Jeff Johnson from Baird set a target price of $85.0 on 08/28/2025
- Larry Biegelsen from Wells Fargo set a target price of $72.0 on 08/28/2025
- Jason Bednar from Piper Sandler set a target price of $83.0 on 08/28/2025
- Robbie Marcus from JP Morgan set a target price of $66.0 on 08/28/2025
Full Release
SAN RAMON, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today its Board of Directors has approved a $1 billion increase in the Company’s share repurchase program. The share repurchase program now totals $2 billion.
“We are pleased to announce that our Board of Directors has authorized an increase to our share repurchase program,” said Al White, President and Chief Executive Officer. “This decision underscores the strength of our balance sheet and cash flow generation, and reflects the Board’s continued confidence in Cooper’s long-term growth trajectory. Returning capital to our shareholders through share repurchases—while continuing to invest and reduce debt—remains aligned with our disciplined capital allocation strategy and commitment to enhancing shareholder value.”
The timing and total amount of share repurchases will depend on market conditions and may be made from time to time in open market purchases or privately negotiated purchases. This program has no termination date, may be suspended or discontinued at any time and does not obligate the company to acquire any amount of common stock.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit
www.coopercos.com
.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the company’s plans to repurchase shares of its common stock. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in these forward-looking statements include: global political and economic conditions; changes in our financial priorities based on evolving business strategies and requirements; and other factors described in CooperCompanies’ Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in CooperCompanies’ Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect Cooper’s analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
[email protected]
